<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        50-5286-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DEFRA 120MG DELAYED RELEASE CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Dimethyl Fumarate
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Delayed-release capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        404.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Macleods Pharmaceuticals Ltd." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Macleods Pharmaceuticals Ltd.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N07XX09 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Defra is a medicine that contains the active substance <strong>dimethyl fumarate</strong>.</p><p><strong>Defra is used to treat relapsing-remitting multiple sclerosis (MS) in adult patients</strong>.</p><p>MS is a long-term condition that affects the central nervous system (CNS), including the brain and the spinal cord. Relapsing-remitting MS is characterised by repeated attacks (relapses) of nervous system symptoms. Symptoms vary from patient to patient, but typically include walking difficulties, feeling off balance and visual difficulties (e.g. blurred or double vision). These symptoms may disappear completely when the relapse is over, but some problems may remain.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take </strong><strong>Name of product </strong><strong>if you:</strong></p><p><strong>if you are allergic to dimethyl fumarate </strong>or any of the other ingredients of this medicine (listed</p><p>in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Defra may affect your <strong>white blood cell counts</strong>, your <strong>kidneys </strong>and <strong>liver</strong>. Before you start</p><p>Defra, your doctor will do a blood test to count the number of your white blood cells and will</p><p>check that your kidneys and liver are working properly. Your doctor will test these periodically during</p><p>treatment. If your number of white blood cells decreases during treatment, your doctor may consider</p><p>interrupting your treatment.</p><p><strong>&nbsp;</strong></p><p>Talk to your doctor before taking Name of product if you:</p><p><strong>- </strong>severe <strong>kidney </strong>disease</p><p><strong>- </strong>severe <strong>liver </strong>disease</p><p><strong>- </strong>a disease of the <strong>stomach </strong>or <strong>bowel</strong></p><p><strong>- </strong>a serious <strong>infection </strong>(such as pneumonia)</p><p>&nbsp;</p><p><strong>Other medicines and Name of product</strong></p><p><strong>Tell your doctor or pharmacist </strong>if you are taking, have recently taken or might take any medicines, in</p><p>particular:</p><p>- medicines that contain <strong>fumaric acid esters </strong>(fumarates) used to treat psoriasis</p><p>- <strong>medicines that affect the body&rsquo;s immune system </strong>including <strong>other medicines used to treat</strong></p><p><strong>MS</strong>, such as fingolimod, natalizumab, teriflunomide, alemtuzumab, ocrelizumab or cladribine,</p><p>or some commonly used <strong>cancer </strong>treatments (rituximab or mitoxantrone).</p><p>- <strong>medicines that affect the kidneys including </strong>some <strong>antibiotics </strong>(used to treat infections), &ldquo;<strong>water</strong></p><p><strong>tablets</strong>&rdquo; (<em>diuretics</em>), <strong>certain types of painkillers </strong>(such as ibuprofen and other similar antiinflammatories</p><p>and medicines purchased without a doctor&rsquo;s prescription) and medicines that</p><p>contain <strong>lithium</strong></p><p>- Taking Defra with certain types of vaccines (<em>live vaccines</em>) may cause you to get an</p><p>infection and should, therefore, be avoided. Your doctor will advise whether other types of</p><p>vaccines (non-live vaccines) should be given.</p><p>&nbsp;</p><p><strong>Name of product with food, drink and alcohol</strong></p><p>Consumption of more than a small quantity (more than 50 ml) of strong alcoholic drinks (more than</p><p>30% alcohol by volume, e.g. spirits) should be avoided within an hour of taking Defra, as alcohol</p><p>can interact with this medicine. This could cause inflammation of the stomach (<em>gastritis</em>), especially in</p><p>people already prone to gastritis.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask</p><p>your doctor or pharmacist for advice before taking this medicine.</p><p><u>Pregnancy</u></p><p>Do not use Defra if you are pregnant unless you have discussed this with your doctor.</p><p><u>Breast-feeding</u></p><p>It is not known whether the active substance of Defra passes into breast milk. Defra should not</p><p>be used during breast-feeding. Your doctor will help you decide whether you should stop breastfeeding,</p><p>or stop using Defra. This involves balancing the benefit of breast-feeding for your child,</p><p>and the benefit of therapy for you.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>The effect of Defra on the ability to drive or use machines is not known. Defra is not expected</p><p>to affect your ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p><strong>Starting dose</strong></p><p><strong>120 mg twice a day.</strong></p><p>Take this starting dose for the first 7 days, then take the regular dose.</p><p><strong>Regular dose</strong></p><p><strong>240 mg twice a day.</strong></p><p>Defra is for oral use</p><p><strong>Swallow each capsule whole</strong>, with some water. Do not divide, crush, dissolve, suck or chew the</p><p>capsule as this may increase some side effects.</p><p><strong>Take Defra with food </strong>&ndash; it may help to reduce some of the very common side effects (listed in</p><p>section 4).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>Defra is not recommended for use in children and adolescents because there is limited experience</p><p>in the use of Defra in this population.</p><p>&nbsp;</p><p><strong>If you take more </strong><strong>Defra </strong><strong>than you should</strong></p><p>If you have taken too many capsules, <strong>talk to your doctor straight away</strong>. You may experience side</p><p>effects similar to those described below in section 4.</p><p><em>&nbsp;</em></p><p><strong>If you forget to take </strong><strong>Defra</strong></p><p>If you forget or miss a dose, <strong>do not take a double dose</strong>.</p><p>You may take the missed dose if you leave at least 4 hours between the doses. Otherwise wait until</p><p>your next planned dose.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious effects</strong></p><p>Moderately low to very low lymphocyte counts - Lymphocyte counts (a type of white blood cell) may</p><p>be decreased for a long period of time. Having a low white blood cell count for a long period of time</p><p>can increase your risk of infection, including a risk of a rare brain infection called progressive</p><p>multifocal leukoencephalopathy (PML). The symptoms of PML may be similar to an MS relapse.</p><p>Symptoms may include new or worsening weakness on one side of the body; clumsiness; changes in</p><p>vision, thinking, or memory; or confusion or personality changes lasting for more than several days.</p><p>&nbsp;</p><p>C<strong>all your doctor straight away if you experience any of these symptoms</strong></p><p><strong>Severe Allergic reactions</strong></p><p>The frequency of severe allergic reactions cannot be estimated from the available data (not known).</p><p>Reddening of the face or body (<em>flushing</em>) is a very common side effect. However, should flushing be</p><p>accompanied by a red rash or hives <strong>and </strong>you get any of these symptoms:</p><p>- swelling of the face, lips, mouth or tongue <em>(angioedema)</em></p><p>- wheezing, difficulty breathing or shortness of breath <em>(dyspnoea, hypoxia)</em></p><p>- dizziness or loss of consciousness <em>(hypotension)</em></p><p>then this may represent a severe allergic reaction <em>(anaphylaxis)</em></p><p> <strong>Stop taking Defra and call a doctor straight away</strong></p><p><strong>Very common side effects</strong></p><p>These may affect <em>more than 1 in 10 people:</em></p><p>- reddening of the face or body feeling warm, hot, burning or itchy <em>(flushing)</em></p><p>- loose stools <em>(diarrhoea)</em></p><p>- feeling sick <em>(nausea)</em></p><p>- stomach pain or stomach cramps</p><p> <strong>Taking your medicine with food </strong>can help to reduce the side effects above</p><p>Substances called ketones, which are naturally produced in the body, very commonly show up in urine</p><p>tests while taking Defra.</p><p><strong>Talk to your doctor </strong>about how to manage these side effects. Your doctor may reduce your dose. Do</p><p>not reduce your dose unless your doctor tells you to.</p><p><strong>Common side effects</strong></p><p>These may affect <em>up to 1 in 10 people:</em></p><p>- inflammation of the lining of the intestines (<em>gastroenteritis</em>)</p><p>- being sick <em>(vomiting)</em></p><p>- indigestion (<em>dyspepsia</em>)</p><p>- inflammation of the lining of the stomach (<em>gastritis</em>)</p><p>- gastrointestinal disorder</p><p>- burning sensation</p><p>- hot flush, feeling hot</p><p>- itchy skin (<em>pruritus</em>)</p><p>- rash</p><p>- pink or red blotches on the skin (<em>erythema</em>)</p><p><u>Side effects which may show up in your blood or urine tests</u></p><p>- low levels of white blood cells (<em>lymphopenia, leucopenia</em>) in the blood. Reduced white</p><p>blood cells could mean your body is less able to fight an infection. If you have a serious</p><p>infection (such as pneumonia), talk to your doctor immediately</p><p>- proteins (<em>albumin</em>) in urine</p><p>- increase in levels of liver enzymes (<em>ALT, AST</em>) in the blood</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong></p><p>These may affect <em>up to 1 in 100 people:</em></p><p>- Allergic reactions (<em>hypersensitivity</em>)</p><p>- reduction in blood platelets</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>- liver inflammation and increase in levels of liver enzymes (<em>ALT or AST in combination with</em></p><p><em>bilirubin</em>)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister and the carton after &ldquo;EXP&rdquo;.</p><p>The expiry date refers to the last day of that month.</p><p>Store below 30&ordm;C, store in dry place.</p><p>Keep the blisters in the outer carton in order to protect from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.<strong>6</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance </strong>is dimethyl fumarate.</p><p>Defra 120 mg: Each capsule contains 120 mg of dimethyl fumarate.</p><p>Defra 240 mg: Each capsule contains 240 mg of dimethyl fumarate.</p><p><strong>The other ingredients</strong></p><p><u>Enteric coated microtablets:</u></p><p>Microcrystalline Cellulose, Croscarmellose Sodium, Colloidal Silicon Dioxide, Magnesium Stearate, Triethyl Citrate, Methacrylic Acid - Ethyl Acrylate Copolymer (1:1), Talc.</p><p><u>Capsule shell:</u></p><p>Gelatin, Water, FD &amp; C Blue, Iron Oxide Black, Iron Oxide Yellow, Titanium Dioxide.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Defra 120mg: Size “0”, light green opaque cap and white opaque body with “I65” and “120 mg” imprinted on body in black ink containing white to off-white film-coated mini-tablet
Defra 240mg: Size “0”, light green opaque cap and light green opaque body with “I66” and “240 mg” imprinted on body in black ink, containing white to off-white film-coated mini-tablets



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p>&nbsp;</p><p><strong>Manufacturer by:</strong></p><p dir="RTL">&nbsp;Macleods Pharmaceuticals LTD &ndash; India &ndash; for MS Pharma &ndash; Saudi</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Oct-19
SPM190383

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إن المادة الفعالة لدواء ديفرا هي ثنائي<strong> ميثيل الفومارات</strong>.</p><p dir="RTL"><strong>يستخدم ديفرا في علاج تصلب الأنسجة&nbsp; المتعدد الناتج عن الانتكاس للمرضى البالغين</strong>.</p><p dir="RTL">يعد مرض التصلب المتعدد هو مرض مزمن يؤثر على الجهاز العصبي المركزي بما في ذلك الدماغ والحبل الشوكي. يتصف مرض التصلب المتعدد الناتج عن الانتكاس بنوباته المتكررة (الانتكاسات) التي تهاجم الجهاز العصبي. تختلف الأعراض من مريض لآخر ولكن غالبًا ما يعاني معظم المرضى من صعوبات في المشي وعدم الاتزان وصعوبات في الرؤية (مثل ازدواجية الرؤية أو ضبابتيها). قد تختفي هذه الأعراض تمامًا عند انتهاء الانتكاسة وقد يبقى بعضها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول دواء ديفرا إذا:</strong></p><p dir="RTL">كانت لديك حساسية ضد ثنائي ميثيل الفومارات أو لأي من المكونات الأخرى في هذا الدواء و(المذكورة في الفقرة 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">قد يؤثر ديفرا على أعداد خلايا الدم البيضاء وعلى<strong> الكليتين</strong> و<strong>الكبد</strong>.</p><p dir="RTL">سيتأكد الطبيب قبل البدء في العلاج بديفرا من أن وظائف الكليتين والكبد تعمل بشكل صحيح. سيقوم بإجراء الفحوصات الدورية أثناء</p><p dir="RTL">فترة العلاج. وربما يلجأ الطبيب في حال نقص عدد خلايا الدم البيضاء أثناء فترة العلاج إلى وقف العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تحدث مع الطبيب قبل تناول الدواء إذا كنت تعاني من:</p><p dir="RTL"><strong>- </strong>&nbsp;مرض<strong> الكلى المزمن</strong></p><p dir="RTL"><strong>- </strong>&nbsp;مرض <strong>الكبد المزمن</strong></p><p dir="RTL"><strong>- </strong>مرض<strong> في المعدة</strong> أو الأمعاء</p><p dir="RTL">عدوى خطيرة (مثل الالتهاب الرئوي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى مع دواء ديفرا</strong></p><p dir="RTL"><strong>أبلغ الطبيب أو الصيدليّ</strong> إذا كنت تتناول أو قد تناولت مؤخرًا أو تنوي تناول أي أدوية أخرى وبالتحديد:</p><p dir="RTL">_ الأدوية التي تحتوي على <strong>حمض الفوماريك</strong> والمستخدم في علاج الصدفية.</p><p dir="RTL">_ <strong>الأدوية التي تؤثر على جهاز المناعة</strong> بما في ذلك<strong> الأدوية الأخرى التي تستخدم في علاج</strong> <strong>مرض التصلب المتعدد مثل فينجوليمود أو ناتاليزوماب أو تيريفلونومايد أو ألميتوزوماب أوأوكرليزوماب أو كلادريبين</strong> <strong>أو بعض الأدوية الشائعة لعلاج السرطان (ريتوكسيماب أو ميتوزانترون).</strong></p><p dir="RTL">_<strong>الأدوية التي تؤثر على الكلى بما في ذلك</strong> بعض <strong>المضادات الحيوية</strong> (المستخدمة في علاج العدوى) و&quot;<strong>أقراص الماء&quot; (مدرات البول وبعض أنواع المسكنات (مثل إيبوبروفين ومضادات الالتهاب المشابهة</strong> <strong>والأدوية التي تصرف بدون وصفة طبية) والأدوية التي</strong> <strong>تحتوي على الليثيوم.</strong></p><p dir="RTL">_ إن تناول ديفرا مع أنواع محددة من اللقاحات (اللقاحات الحية) يمكن أن يتسبب في إصابتك بالعدوى ولذلك يجب الابتعاد عنها. سيقرر الطبيب إمكانية أخذك لأنواع أخرى من اللقاحات (اللقاحات غير الحية) من عدمه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تداخل الدواء مع الأطعمة والمشروبات والكحوليات</strong></p><p dir="RTL">يجب الامتناع عن شرب الكميات الكبيرة (أكثر من 50مل) من المشروبات الكحولية القوية (لا تتعدى نسبة الكحول أكثر من30% مثل على سبيل المثال المشروبات الروحية) وذلك قبل ساعة من تناول ديفرا حيث أن الكحول يمكن له التفاعل مع هذا الدواء. مما قد يتسبب في التهاب المعدة (الالتهاب المعوي) وخصوصًا في الأشخاص الأكثر عرضة للإصابة بالالتهاب المعوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يجب استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء في حالة السيدات الحوامل أو السيدات اللاتي تقمن بالرضاعة الطبيعية أو في حالات التخطيط لحدوث الحمل أو في حالة الشك بوجود حمل.</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">لا تقومي بتناول <strong>ديفرا</strong> إذا كنت حاملًا إلا إذا استشرتي الطبيب.</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">لا نعلم إذا كان ديفرا يُفرز في لبن الأم أم لا. لا يجب تناول ديفرا</p><p dir="RTL">أثناء فترة الرضاعة الطبيعية. سيساعدك الطبيب في معرفة القرار الصحيح عما إذا كان يجب عليك التوقف عن الرضاعة الطبيعية أو التوقف عن تناول ديفرا. فيتضمن ذلك القرار تحقيق التوازن بين فائدة الرضاعة الطبيعية لطفلك واستفادتك من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لم نستطع معرفة مدى تأثير ديفرا في القدرة على القيادة واستخدام الآلات. ليس من المتوقع أن يؤثر ديفرا على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك تناول هذا الدواء وفقًا لتعليمات الطبيب. في حالة عدم تأكدك من أي شيء، يرجى سؤال الطبيب.</p><p dir="RTL"><strong>الجرعة الأولية</strong></p><p dir="RTL"><strong>120 ملغم مرتان يوميًا.</strong></p><p dir="RTL">تُؤخذ هذه الجرعة الأولية في أول سبع أيام ومن ثم يتم أخذ الجرعة العادية.</p><p dir="RTL"><strong>الجرعة العادية</strong></p><p dir="RTL"><strong>240 ملغم مرتان يوميًا.</strong></p><p dir="RTL">يُؤخذ <strong>ديفرا</strong> عن طريق الفم</p><p dir="RTL"><strong>قم ببلع الكبسولة بأكملها</strong> مع تناول بعض السوائل. لا تقم بتقسيم أو تفتيت أو تذويب أو مص أو مضغ الكبسولة لأن ذلك من شأنه زيادة معدل حدوث الآثار الجانبية.</p><p dir="RTL"><strong>تناول ديفرا مع الطعام </strong>_قد يساعد في تقليل معدل حدوث الآثار الجانبية الشائعة (المذكورة في الفقرة 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام الدواء مع الأطفال والمراهقين</strong></p><p dir="RTL">لا ينصح بتناول هذا الدواء في الأطفال والمراهقين لأنه لم يتم تجربته بشكل كافي مع هذه الفئات العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت أكثر من الجرعات الموصي بها من الدواء ديفرا</strong></p><p dir="RTL"><strong>تحدث إلى طبيبك على الفور</strong> إذا قمت بتناول الكثير من الكبسولات. يمكن أن تحدث لك آثار جانبية تشابه الآثار المذكورة أدناه في فقرة 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول دواء ديفرا</strong></p><p dir="RTL">إذا نسيت تناول جرعة من الجرعات أو فاتتك <strong>لا تقم بمضاعفة الجرعة</strong>.</p><p dir="RTL">يمكن أن تأخذ الجرعة الفائتة في حال بقي على الأقل 4 ساعات على موعد الجرعة القادمة. وإلا انتظر حتى يحين موعد جرعتك القادمة.</p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL">قد تنخفض عدد الخلايا اللمفاوية بشكل منخفض جداً -الخلايا اللمفاوية (نوع من الخلايا البيضاء) لفتر ة طويلة من الزمن وجود انخفاض في عدد خلايا الدم البيضاء لفترة طويلة من الزمن يمكن أن تزيد من خطر العدوى، بما في ذلك خطر حدوث عدوى نادرة في الدماغ تسمى تعدد البؤر المترقية (اعتلال بيضاء الدماغ المتعدد البؤر) وقد تكون أعراض اعتلال بيضاء الدماغ المتعدد البؤر مماثلة لأعراض مرض التصلب المتعدد وقد تتضمن الأعراض ضعفًا جديدًا أو سوءًا على جانب واحد من الجسم أو خرق أو تغييرات في الرؤية أو التفكير أو الذاكرة أو الارتباك أو التغييرات الشخصية تستمر لأكثر من عدة أيام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر الطبيب على الفور عند ملاحظة أي من هذه الأعراض:</strong></p><p dir="RTL"><strong>علاج رد الفعل التحسسي الشديد</strong></p><p dir="RTL">العديد من أعراض الفعل التحسسي الشديد تعتبر أعراض جانبية لا يمكن تحديد نسبة تكرارها من البيانات المتاحة (غير معروف)</p><p dir="RTL">احمرار الوجه أو الجسم (التوهج) هو أحد الآثار الجانبية الشائعة. ومع ذلك، قد يكون التوهج مصحوبًا بطفح جلدي أو خلايا حمراء <strong>و</strong>تصاب بأي من هذه الأعراض:</p><p dir="RTL">- تورم في الوجه أو الشفاه أو الفم أو اللسان. (الوذمة الوعائية)</p><p dir="RTL">- التنفس، صعوبة في التنفس أو قصر التنفس (صعوبة التنفس، نقص الأكسجين)</p><p dir="RTL">- الدوار أو فقدان الوعي (انخفاض ضغط الدم)</p><p dir="RTL">عندئذ فقد يمثل هذا رد فعل تحسسي شديد (الحساسية المفرطة)</p><p dir="RTL"><strong>التوقف عن تناول ديفرا واستدعاء الطبيب على الفور</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL">الأعراض التي قد تؤثر على أكثر من 1 من بين 10 أشخاص</p><p dir="RTL">- احمرار الوجه أو الجسم والشعور بالدفء أو السخونة أو الحرقان أو الحكة(التوهج)</p><p dir="RTL">- الإسهال (الإسهال)</p><p dir="RTL">الشعور بالتعب(الغثيان)</p><p dir="RTL">ألم في المعدة أو تقلصات في المعدة</p><p dir="RTL"><strong>تناول الدواء مع الطعام </strong>يمكن أن يساعد في تقليل الآثار الجانبية المذكورة أعلاه</p><p dir="RTL">المواد التي تسمى الأجسام الكيتونية والتي يتم إنتاجها بشكل طبيعي في الجسم وتظهر بشكل شائع في اختبارات البول أثناء تناول ديفرا.</p><p dir="RTL"><strong>تحدث مع طبيبك</strong> حول كيفية التعامل مع هذه الآثار الجانبية. قد يقلل طبيبك الجرعة الخاصة بك. لا</p><p dir="RTL">تقلل الجرعة إلا إذا أخبرك طبيبك بذلك.</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL">الآثار الجانبية الشائعة التي (قد تؤثر في 1 من بين 10 أشخاص):</p><p dir="RTL">- التهاب بطانة الأمعاء (نزلة معوية)</p><p dir="RTL">- الشعور بالغثيان (القيء)</p><p dir="RTL">- عسر الهضم (عسر الهضم)</p><p dir="RTL">- التهاب بطانة المعدة (التهاب معوي)</p><p dir="RTL">- اضطراب الجهاز الهضمي</p><p dir="RTL">- الشعور بالحرقان</p><p dir="RTL">- احمرار الجسم والشعور بالسخونة</p><p dir="RTL">- الحكة في الجلد (الشعور بالحكة)</p><p dir="RTL">- طفح جلدي</p><p dir="RTL">- بقع وردية أو حمراء على الجلد (احمرار الجلد)</p><p dir="RTL"><strong><u>الآثار الجانبية التي قد تظهر في اختبارات الدم أو البول</u></strong></p><p dir="RTL">- نقص عدد كرات الدم البيضاء (قلة الليمفاويات، نقص كريات الدم البيضاء) في الدم عند نقص كريات الدم البيضاء في دمك سيصبح جسمك أقل قدرة على مكافحة العدوي إذا كنت تعاني من عدوى خطيرة (مثل الالتهاب الرئوي)، فتحدث إلى طبيبك على الفور</p><p dir="RTL">- البروتين (ألبومين بشري) في البول</p><p dir="RTL">ارتفاع مستوى إنزيمات الكبد في الدم (الناقل الأميني للألانين، الناقل الأميني للأسبارتات)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong></p><p dir="RTL">الآثار الجانبية الشائعة التي (قد تؤثر في 1 من بين 100 أشخاص):</p><p dir="RTL">- رد فعل تحسسي (الحساسية المفرطة)</p><p dir="RTL">- نقص في عدد الصفائح الدموية</p><p dir="RTL"><strong>الآثار الجانبية غير المعروفة</strong> (لا يمكن تحديد نسبة تكرار الأعراض من البيانات المتاحة)</p><p dir="RTL">- التهاب في الكبد وزيادة في مستوي إنزيمات الكبد (الناقل الأميني للألانين، الناقل الأميني للأسبارتات مجتمعة مع</p><p dir="RTL">(البليروبين)</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيدا عن متناول الأطفال. لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على شريط الكبسولات وعلى العبوة بعد كلمة &quot;انتهاء&quot;. حيث يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية ، يحفظ في مكان جاف .</p><p dir="RTL">&nbsp;وقم بحفظ الشرائط في عبوتها من أجل حمايته من الضوء.</p><p dir="RTL">لا تقم بإلقاء أية أدوية في مياه الصرف أو في النفايات المنزلية.&nbsp; قم باستشارة الصيدلي الخاص بك عن كيفية التخلص الآمن من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في المحافظة على البيئة. <strong>6</strong></p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي محتويات الدواء</strong></p><p dir="RTL"><strong>المادة الفعالة</strong>: دايمثيل فومارات.</p><p dir="RTL">ديفرا 120ملغم: تحتوي كل كبسولة على 120ملغم من دايميثيل فومارات.</p><p dir="RTL">ديفرا 240ملغم تحتوي كل كبسولة على 240ملغم من دايميثيل فومارات.</p><p dir="RTL"><strong>المكونات الأخرى</strong></p><p dir="RTL"><u>تغليف معوي على الكبسولات الصغيرة:</u></p><p dir="RTL">سليلوز دقيق البلورات، كارميلوز الصوديوم، ثاني أكسيد السيليكون الغروي، استيارات الماغنيسيوم، ثلاثي إيثيل السيترات، بوليمر مشترك من حمض الإيثاكرينيك -إيثيل أكريليت (1:1) التالك.</p><p dir="RTL"><u>المحتويات الموجودة في الكبسولة:</u></p><p dir="RTL">الجيلاتين، المياة، أزرق براق إف دي إف، أكسيد الحديد الأسود، أكسيد الحديد الأصفر، ثاني أكسيد التيتانيوم.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ديفرا<strong> 120ملغم</strong>: حجم&quot;0&quot;، غطاء معتدل أخضر فاتح وجسم معتدل أبيض اللون مقاس &quot;165&quot; و &quot;120 ملغم&quot; في هيئة حبر أسود ويحتوي على محتويات الغشاء المغلف للكبسولة</p><p dir="RTL">ديفرا <strong>240ملغم:</strong> حجم&quot;0&quot;، غطاء معتدل أخضر فاتح وجسم معتدل أبيض اللون مقاس &quot;166&quot; و &quot;240ملغم&quot; في هيئة حبر أسود ويحتوي على محتويات الغشاء المغلف للكبسولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إم إس فارما السعودية</p><p dir="RTL">الرياض ، المملكة العربية السعودية .</p><p>&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:&nbsp; </strong><strong>&nbsp;</strong></p><p dir="RTL"><strong>ماكلويدز للمستحضرات الدوائية المحدودة &ndash; الهند</strong> <strong>&ndash; لصالح إم إس فارما &ndash; السعودية.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Oct-19
SPM190383

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 DEFRA ® 120mg delayed release capsules 
DEFRA ® 240mg delayed release capsules 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
 DEFRA ® 120mg delayed release capsules 
Each capsule contains 120 mg dimethyl fumarate. 
DEFRA ® 240mg delayed release capsules 
Each capsule contains 240 mg dimethyl fumarate
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Delayed release capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>&nbsp;DEFRA<sup>&reg; </sup>is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5.1 for important information on the populations for which efficacy has been established).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated under supervision of a physician experienced in the treatment of multiple sclerosis.</p><p><u>Posology </u></p><p>The starting dose is 120 mg twice a day. After 7 days, the dose should be increased to the recommended maintenance dose of 240 mg twice a day (see section 4.4).</p><p>&nbsp;</p><p>If a patient misses a dose, a double dose should not be taken. The patient may take the missed dose only if they leave 4 hours between doses. Otherwise the patient should wait until the next scheduled dose.</p><p>Temporary dose reduction to 120 mg twice a day may reduce the occurrence of flushing and gastrointestinal adverse reactions. Within 1 month, the recommended maintenance dose of 240 mg twice a day should be resumed.</p><p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong>should be taken with food (see section 5.2). For those patients who may experience flushing or gastrointestinal adverse reactions, taking <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>with food may improve tolerability (see sections 4.4, 4.5 and 4.8).</p><p><em>Special populations </em></p><p><em>Elderly </em></p><p>Clinical studies of <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>had limited exposure to patients aged 55 years and above, and did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients (see section 5.2). Based on the mode of action of the active substance there are no theoretical reasons for any requirement for dose adjustments in the elderly.</p><p><em>Renal and hepatic impairment </em></p><p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong>has not been studied in patients with renal or hepatic impairment. Based on clinical pharmacology studies, no dose adjustments are needed (see section 5.2). Caution should be used when treating patients with severe renal or severe hepatic impairment (see section 4.4).</p><p><em>Paediatric population </em></p><p>The safety and efficacy of <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>in children and adolescents aged 10 to 18 years have not yet been established.</p><p>Currently available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be made. There is no relevant use of <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>in children aged less than 10 years for the indication of relapsing remitting multiple sclerosis.</p><p><u>Method of administration </u></p><p>For oral use.</p><p>The capsule should be swallowed whole. The capsule or its contents should not be crushed, divided, dissolved, sucked or chewed as the enteric-coating of the microtablets prevents irritant effects on the gut.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>&nbsp;</u></strong></p><p><u>Blood/laboratory tests </u></p><p>Changes in renal laboratory tests have been seen in clinical trials in subjects treated with dimethyl fumarate (see section 4.8). The clinical implications of these changes are unknown. Assessment of renal function (e.g. creatinine, blood urea nitrogen and urinalysis) is recommended prior to treatment initiation, after 3 and 6 months of treatment, every 6 to 12 months thereafter and as clinically indicated.</p><p>Drug-induced liver injury, including liver enzyme increase (&ge; 3 upper limit of normal (ULN)) and elevation of total bilirubin levels (&ge; 2 ULN) can result from treatment with dimethyl fumarate. The time to onset can be directly, several weeks or longer. Resolution of the adverse reactions has been observed after treatment was discontinued. Assessment of serum aminotransferases (e.g. alanine aminotransferase (ALT), aspartate aminotransferase (AST)) and total bilirubin levels are recommended prior to treatment initiation and during treatment as clinically indicated.</p><p>Patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>may develop severe prolonged lymphopenia (see section 4.8). Dimethyl fumarate has not been studied in patients with pre-existing low lymphocyte counts and caution should be exercised when treating these patients. Prior to initiating treatment with <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>, a current complete blood count, including lymphocytes, must be performed. If lymphocyte count is found to be below the normal range, thorough assessment of possible causes should be completed prior to initiation of treatment with <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>.</p><p>After starting therapy, complete blood counts, including lymphocytes, must be performed every 3 months.</p><p>Interruption of <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>should be considered in patients with lymphocyte counts &lt;0.5x10<sup>9</sup>/L persisting for more than 6 months. The benefit/risk balance of the therapy should be reconsidered in discussion with the patient in the context of other therapeutic options available. Clinical factors, evaluation of any laboratory and imaging investigations could be included as part of this re-consideration. If treatment is continued despite a persistent lymphocyte count &lt; 0.5x10<sup>9</sup>/L, enhanced vigilance is recommended (see also subsection on PML). Lymphocyte counts should be followed until recovery. Upon recovery and in the absence of alternative treatment options, decisions about whether or not to restart <strong>DEFRA</strong></p><p><strong>&reg; </strong>after treatment discontinuation should be based on clinical judgement.</p><p>The benefit/risk in patients with lymphocyte counts &ge;0.5 x 109/L and &lt;0.8 x 109/L for more than six months should be assessed.</p><p>Magnetic Resonance imaging (MRI)</p><p>Before initiating treatment with <strong>DEFRA </strong><strong>&reg;</strong>, a baseline MRI should be available (usually within 3 months) as a reference. The need for further MRI scanning should be considered in accordance with national and local recommendations. MRI imaging may be considered as part of increased vigilance in patients considered at increased risk of PML. In case of clinical suspicion of PML, MRI should be performed immediately for diagnostic purposes.</p><p>Progressive Multifocal Leukoencephalopathy (PML)</p><p>PML cases have occurred with dimethyl fumarate and other medicinal products containing fumarates in the setting of moderate to severe prolonged lymphopenia. PML is an opportunistic infection caused by John-Cunningham virus (JCV), which may be fatal or result in severe disability. PML can only occur in the presence of a JCV infection. If JCV testing is undertaken, it should be considered that the influence of lymphopenia on the accuracy of anti-JCV antibody test has not been studied in dimethyl fumarate treated patients. It should also be noted that a negative anti JCV antibody test (in the presence of normal lymphocyte counts) does not preclude the possibility of subsequent JCV infection.</p><p>At the first sign or symptom suggestive of PML, <strong>DEFRA </strong><strong>&reg; </strong>should be withheld and appropriate diagnostic evaluations need to be performed. The symptoms of PML may be similar to an MS relapse. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.</p><p>Prior treatment with immunosuppressive or immunomodulating therapies</p><p>No studies have been performed evaluating the efficacy and safety of <strong>DEFRA </strong><strong>&reg; </strong>when switching patients from other disease modifying therapies to <strong>DEFRA </strong><strong>&reg;</strong>. The contribution of prior immunosuppressive therapy to the development of PML in dimethyl fumarate treated patients is unknown. When switching patients from another disease modifying therapy to <strong>DEFRA </strong><strong>&reg;</strong>, the half-life and mode of action of the other therapy should be considered in order to avoid an additive immune effect while at the same time, reducing the risk of reactivation of MS. A complete blood count is recommended prior to initiating <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>and regularly during treatment (see Blood/laboratory tests above).</p><p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong>can generally be started immediately after discontinuation of interferon or glatiramer acetate.</p><p><u>Severe renal and hepatic impairment </u></p><p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong>has not been studied in patients with severe renal or severe hepatic impairment and caution should, therefore, be used in these patients (see section 4.2).</p><p><u>Severe active gastrointestinal disease </u></p><p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong>has not been studied in patients with severe active gastrointestinal disease and caution should, therefore, be used in these patients.</p><p><u>Flushing </u></p><p>In clinical trials, 34% of <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>treated patients experienced flushing. In the majority of patients who experienced flushing, it was mild or moderate in severity. Data from healthy volunteer studies suggest that dimethyl fumarate-associated flushing is likely to be prostaglandin mediated. A short course of treatment with 75 mg non-enteric coated acetylsalicylic acid may be beneficial in patients affected by intolerable flushing (see section 4.5). In two healthy volunteer studies, the occurrence and severity of flushing over the dosing period was reduced.</p><p>In clinical trials, 3 patients out of a total of 2,560 patients treated with dimethyl fumarate experienced serious flushing symptoms that were probable hypersensitivity or anaphylactoid reactions. These events were not life-threatening, but led to hospitalisation. Prescribers and patients should be alert to this possibility in the event of severe flushing reactions (see sections 4.2, 4.5 and 4.8).</p><p><u>Anaphylactic reactions </u></p><p>Cases of anaphylaxis/anaphylactoid reaction have been reported following <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>administration in the post-marketing setting. Symptoms may include dyspnoea, hypoxia, hypotension, angioedema, rash or urticaria. The mechanism of dimethyl fumarate induced anaphylaxis is unknown. Reactions generally occur after the first dose, but may also occur at any time during treatment, and may be serious and life threatening. Patients should be instructed to discontinue <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>and seek immediate medical care if they experience signs or symptoms of anaphylaxis. Treatment should not be restarted (see section 4.8).</p><p><u>Infections</u></p><p><u>&nbsp;</u></p><p>In phase III placebo-controlled studies, the incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>or placebo, respectively. However, due to <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>immunomodulatory properties (see section 5.1), if a patient develops a serious infection, suspending treatment with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>should be considered and the benefits and risks should be reassessed prior to re-initiation of therapy. Patients receiving <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>should be instructed to report symptoms of infections to a physician. Patients with serious infections should not start treatment with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>until the infection(s) is resolved.</p><p>There was no increased incidence of serious infections observed in patients with lymphocyte counts &lt;0.8x10<sup>9</sup>/L or &lt;0.5x10<sup>9</sup>/L (see Section 4.8). If therapy is continued in the presence of moderate to severe prolonged lymphopenia, the risk of an opportunistic infection, including PML, cannot be ruled out (see section 4.4 subsection PML).</p><p><u>Treatment initiation </u></p><p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong>treatment should be started gradually to reduce the occurrence of flushing and gastrointestinal adverse reactions (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong>has not been studied in combination with anti-neoplastic or immunosuppressive therapies and caution should, therefore, be used during concomitant administration. In multiple sclerosis clinical studies, the concomitant treatment of relapses with a short course of intravenous corticosteroids was not associated with a clinically relevant increase of infection.</p><p>Concomitant administration of non-live vaccines according to national vaccination schedules may be considered during <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>therapy. In a clinical study involving a total of 71 patients with relapsing remitting multiple sclerosis, patients on <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>240 mg twice daily for at least 6 months (n=38) or non-pegylated interferon for at least 3 months (n=33), mounted a comparable immune response (defined as &ge;2-fold increase from pre- to post-vaccination titer) to tetanus toxoid (recall antigen) and a conjugated meningococcal C polysaccharide vaccine (neoantigen), while the immune response to different serotypes of an unconjugated 23-valent pneumococcal polysaccharide vaccine (T-cell independent antigen) varied in both treatment groups. A positive immune response defined as a &ge;4-fold increase in antibody titer to the three vaccines, was achieved by fewer subjects in both treatment groups. Small numerical differences in the response to tetanus toxoid and pneumococcal serotype 3 polysaccharide were noted in favour of non-pegylated interferon.</p><p>No clinical data are available on the efficacy and safety of live attenuated vaccines in patients taking <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>. Live vaccines might carry an increased risk of clinical infection and should not be given to patients treated with <strong>DEFRA</strong></p><p><strong>&reg; </strong>unless, in exceptional cases, this potential risk is considered to be outweighed by the risk to the individual of not vaccinating.</p><p>During treatment with <strong>DEFRA </strong><strong>&reg;</strong>, simultaneous use of other fumaric acid derivatives (topical or systemic) should be avoided.</p><p>In humans, dimethyl fumarate is extensively metabolised by esterases before it reaches the systemic circulation and further metabolism occurs through the tricarboxylic acid cycle, with no involvement of the cytochrome P450 (CYP) system. Potential drug interaction risks were not identified from <em>in vitro </em>CYP-inhibition and induction studies, a p-glycoprotein study, or studies of the protein binding of dimethyl fumarate and monomethyl fumarate (a primary metabolite of dimethyl fumarate).</p><p>Commonly used medicinal products in patients with multiple sclerosis, intramuscular interferon beta-1a and glatiramer acetate, were clinically tested for potential interactions with dimethyl fumarate and did not alter the pharmacokinetic profile of dimethyl fumarate.</p><p>Evidence from healthy volunteer studies suggests that <strong>DEFRA </strong><strong>&reg; </strong>-associated flushing is likely to be prostaglandin mediated. In two healthy volunteer studies, the administration of 325 mg (or equivalent) non-enteric coated acetylsalicylic acid, 30 minutes prior to <strong>DEFRA </strong><strong>&reg;</strong>, dosing over 4 days and over 4 weeks, respectively, did not alter the pharmacokinetic profile of. Potential risks associated with acetylsalicylic acid therapy should be considered prior to co-administration with <strong>DEFRA </strong><strong>&reg; </strong>in patients with Relapsing Remitting MS. Long term (&gt; 4 weeks) continuous use of acetylsalicylic acid has not been studied (see sections <strong>DEFRA </strong><strong>&reg; </strong>4.4 and 4.8).</p><p>Concurrent therapy with nephrotoxic medicinal products (such as aminoglycosides, diuretics, non-steroidal anti-inflammatory drugs or lithium) may increase the potential of renal adverse reactions (e.g. proteinuria see section 4.8) in patients taking <strong>DEFRA </strong><strong>&reg; </strong>(see section 4.4 Blood/laboratory tests).</p><p>Consumption of moderate amounts of alcohol did not alter exposure to dimethyl fumarate and was not associated with an increase in adverse reactions. Consumption of large quantities of strong alcoholic drinks (more than 30% alcohol by volume) should be avoided within an hour of taking <strong>DEFRA </strong><strong>&reg;</strong>, as alcohol may lead to increased frequency of gastrointestinal adverse reactions.</p><p><em>In vitro </em>CYP induction studies did not demonstrate an interaction between <strong>DEFRA </strong><strong>&reg; </strong>and oral contraceptives. In an <em>in vivo </em>study, co-administration of <strong>DEFRA </strong><strong>&reg; </strong>with a combined oral contraceptive (norgestimate and ethinyl estradiol) did not elicit any relevant change in oral contraceptive exposure. No interaction studies have been performed with oral contraceptives containing other progestogens, however an effect of <strong>DEFRA </strong><strong>&reg; </strong>on their exposure is not expected.</p><p>Paediatric population</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong>has not been studied in combination with anti-neoplastic or immunosuppressive therapies and caution should, therefore, be used during concomitant administration. In multiple sclerosis clinical studies, the concomitant treatment of relapses with a short course of intravenous corticosteroids was not associated with a clinically relevant increase of infection.</p><p>Concomitant administration of non-live vaccines according to national vaccination schedules may be considered during <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>therapy. In a clinical study involving a total of 71 patients with relapsing remitting multiple sclerosis, patients on <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>240 mg twice daily for at least 6 months (n=38) or non-pegylated interferon for at least 3 months (n=33), mounted a comparable immune response (defined as &ge;2-fold increase from pre- to post-vaccination titer) to tetanus toxoid (recall antigen) and a conjugated meningococcal C polysaccharide vaccine (neoantigen), while the immune response to different serotypes of an unconjugated 23-valent pneumococcal polysaccharide vaccine (T-cell independent antigen) varied in both treatment groups. A positive immune response defined as a &ge;4-fold increase in antibody titer to the three vaccines, was achieved by fewer subjects in both treatment groups. Small numerical differences in the response to tetanus toxoid and pneumococcal serotype 3 polysaccharide were noted in favour of non-pegylated interferon.</p><p>No clinical data are available on the efficacy and safety of live attenuated vaccines in patients taking <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>. Live vaccines might carry an increased risk of clinical infection and should not be given to patients treated with <strong>DEFRA</strong></p><p><strong>&reg; </strong>unless, in exceptional cases, this potential risk is considered to be outweighed by the risk to the individual of not vaccinating.</p><p>During treatment with <strong>DEFRA </strong><strong>&reg;</strong>, simultaneous use of other fumaric acid derivatives (topical or systemic) should be avoided.</p><p>In humans, dimethyl fumarate is extensively metabolised by esterases before it reaches the systemic circulation and further metabolism occurs through the tricarboxylic acid cycle, with no involvement of the cytochrome P450 (CYP) system. Potential drug interaction risks were not identified from <em>in vitro </em>CYP-inhibition and induction studies, a p-glycoprotein study, or studies of the protein binding of dimethyl fumarate and monomethyl fumarate (a primary metabolite of dimethyl fumarate).</p><p>Commonly used medicinal products in patients with multiple sclerosis, intramuscular interferon beta-1a and glatiramer acetate, were clinically tested for potential interactions with dimethyl fumarate and did not alter the pharmacokinetic profile of dimethyl fumarate.</p><p>Evidence from healthy volunteer studies suggests that <strong>DEFRA </strong><strong>&reg; </strong>-associated flushing is likely to be prostaglandin mediated. In two healthy volunteer studies, the administration of 325 mg (or equivalent) non-enteric coated acetylsalicylic acid, 30 minutes prior to <strong>DEFRA </strong><strong>&reg;</strong>, dosing over 4 days and over 4 weeks, respectively, did not alter the pharmacokinetic profile of. Potential risks associated with acetylsalicylic acid therapy should be considered prior to co-administration with <strong>DEFRA </strong><strong>&reg; </strong>in patients with Relapsing Remitting MS. Long term (&gt; 4 weeks) continuous use of acetylsalicylic acid has not been studied (see sections <strong>DEFRA </strong><strong>&reg; </strong>4.4 and 4.8).</p><p>Concurrent therapy with nephrotoxic medicinal products (such as aminoglycosides, diuretics, non-steroidal anti-inflammatory drugs or lithium) may increase the potential of renal adverse reactions (e.g. proteinuria see section 4.8) in patients taking <strong>DEFRA </strong><strong>&reg; </strong>(see section 4.4 Blood/laboratory tests).</p><p>Consumption of moderate amounts of alcohol did not alter exposure to dimethyl fumarate and was not associated with an increase in adverse reactions. Consumption of large quantities of strong alcoholic drinks (more than 30% alcohol by volume) should be avoided within an hour of taking <strong>DEFRA </strong><strong>&reg;</strong>, as alcohol may lead to increased frequency of gastrointestinal adverse reactions.</p><p><em>In vitro </em>CYP induction studies did not demonstrate an interaction between <strong>DEFRA </strong><strong>&reg; </strong>and oral contraceptives. In an <em>in vivo </em>study, co-administration of <strong>DEFRA </strong><strong>&reg; </strong>with a combined oral contraceptive (norgestimate and ethinyl estradiol) did not elicit any relevant change in oral contraceptive exposure. No interaction studies have been performed with oral contraceptives containing other progestogens, however an effect of <strong>DEFRA </strong><strong>&reg; </strong>on their exposure is not expected.</p><p>Paediatric population</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong>has no or negligible influence on the ability to drive and use machines. No studies on the ability to drive and use machines have been conducted but no effects potentially influencing this ability were found to be related to dimethyl fumarate in clinical studies</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile </u></p><p>The most common adverse reactions (incidence &ge;10%) for patients treated with dimethyl fumarate were flushing and gastrointestinal events (i.e. diarrhoea, nausea, abdominal pain, abdominal pain upper). Flushing and gastrointestinal events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience flushing and gastrointestinal events, these events may continue to occur intermittently throughout treatment with <strong>DEFRA</strong></p><p><strong>&reg;</strong>. The most commonly reported adverse reactions leading to discontinuation (incidence &gt;1%) in patients treated with <strong>DEFRA </strong><strong>&reg; </strong>were flushing (3%) and gastrointestinal events (4%).</p><p>In placebo-controlled and uncontrolled clinical studies, a total of 2,468 patients have received <strong>DEFRA </strong><strong>&reg; </strong>and been followed for periods up to 4 years with an overall exposure equivalent to 3,588 person-years. Approximately 1,056 patients have received more than 2 years of treatment with <strong>DEFRA </strong><strong>&reg;</strong>. The experience in uncontrolled clinical trials is consistent with the experience in the placebo-controlled clinical trials.</p><p>Tabulated summary of adverse reactions</p><p>Adverse reactions, which were more frequently reported in <strong>DEFRA </strong><strong>&reg; </strong>versus placebo-treated patients, are presented in the table below. These data were derived from 2 pivotal Phase 3 placebo-controlled, double-blind clinical trials with a total of 1,529 patients treated with <strong>DEFRA </strong><strong>&reg; </strong>and for up to 24 months with an overall exposure of 2,371 person-years (see section 5.1). The frequencies described in the table below are based on 769 patients treated with <strong>DEFRA </strong><strong>&reg; </strong>240 mg twice a day and 771 patients treated with placebo</p><p>The adverse reactions are presented as MedDRA preferred terms under the MedDRA System Organ Class. The incidence of the adverse reactions below are expressed according to the following categories:</p><p>- Very common (&ge;1/10)</p><p>- Common (&ge;1/100 to &lt;1/10)</p><p>- Uncommon (&ge;1/1, 000 to &lt;1/100)</p><p>- Rare (&ge;1/10, 000 to &lt;1/1,000)</p><p>- Very rare (&lt;1/10,000)</p><p>- Not known (frequency cannot be estimated from the available data)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:660px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Progressive multifocal leukoencephalopathy (PML) 1</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leucopenia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylaxis1</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea1</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypoxia1</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension1</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema1</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Burning sensation</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hot flush</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain upper</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gastrointestinal disorder</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug-induced liver injury1</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Proteinuria</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Feeling hot</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Ketones measured in urine</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Albumin urine present</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>White blood cell count decreased</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong><em><sup>1 </sup></em></strong><em>Adverse reactions derived only during post marketing experience </em></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Flushing </em></p><p>In the placebo-controlled studies, the incidence of flushing (34% versus 4%) and hot flush (7% versus 2%) was increased in patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>compared to placebo, respectively. Flushing is usually described as flushing or hot flush, but can include other events (e.g. warmth, redness, itching, and burning sensation). Flushing events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience flushing, these events may continue to occur intermittently throughout treatment with <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>. In patients with flushing, the majority had flushing events that were mild or moderate in severity. Overall, 3% of patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>discontinued due to flushing. The incidence of serious flushing, which may be characterised by generalised erythema, rash and/or pruritus, was seen in less than 1% of patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>(see sections 4.2, 4.4 and 4.5).</p><p><em>Gastrointestinal </em></p><p>The incidence of gastrointestinal events (e.g. diarrhoea [14% versus 10%], nausea [12% versus 9%], upper abdominal pain [10% versus 6%], abdominal pain [9% versus 4%], vomiting [8% versus 5%] and dyspepsia [5% versus 3%]) was increased in patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>compared to placebo, respectively. Gastrointestinal events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience gastrointestinal events, these events may continue to occur intermittently throughout treatment with <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>. In the majority of patients who experienced gastrointestinal events, it was mild or moderate in severity. Four per cent (4%) of patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>discontinued due to gastrointestinal events. The incidence of serious gastrointestinal events, including gastroenteritis and gastritis, was seen in 1% of patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>(see section 4.2).</p><p><em>Hepatic function </em></p><p>Based on data from placebo-controlled studies, the majority of patients with elevations had hepatic transaminases that were &lt;3 times the upper limit of normal (ULN). The increased incidence of elevations of hepatic transaminases in patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>relative to placebo was primarily seen during the first 6 months of treatment. Elevations of alanine aminotransferase and aspartate aminotransferase &ge;3 times ULN, respectively, were seen in 5% and 2% of patients treated with placebo and 6% and 2% of patients treated with <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>. Discontinuations due to elevated hepatic transaminases were &lt;1% and similar in patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>or placebo. Elevations in transaminases &ge;3 times ULN with concomitant elevations in total bilirubin &gt;2 times ULN, were not observed in placebo-controlled studies.</p><p>Increase of liver enzymes and cases of drug-induced liver injury (elevations in transaminases &ge;3 times ULN with concomitant elevations in total bilirubin &gt;2 times ULN), have been reported in post marketing experience following <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>administration, which resolved upon treatment discontinuation.</p><p><em>Lymphopenia </em></p><p>In the placebo-controlled studies most patients (&gt;98%) had normal lymphocyte values prior to initiating treatment. Upon treatment with <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>, mean lymphocyte counts decreased over the first year with a subsequent plateau. On average, lymphocyte counts decreased by approximately 30% of baseline value. Mean and median lymphocyte counts remained within normal limits. Lymphocyte counts &lt;0.5x10<sup>9</sup>/l were observed in &lt;1% of patients treated with placebo and 6% of patients treated with <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>. A lymphocyte count &lt;0.2x10<sup>9</sup>/l was observed in 1 patient treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>and in no patients treated with placebo.</p><p>In clinical studies (both controlled and uncontrolled), 9% of patients had lymphocyte counts &ge;0.5 x 10<sup>9</sup>/L and &lt;0.8 x 10<sup>9</sup>/L for at least six months; 2% of patients experienced lymphocyte counts &lt;0.5 x 10<sup>9</sup>/L for at least six months, and in this group the majority of lymphocyte counts remained &lt;0.5 x 10<sup>9</sup>/L with continued therapy.</p><p>PML has occurred in the setting of moderate to severe prolonged lymphopenia (see section 4.4).</p><p><em>Laboratory abnormalities </em></p><p>In the placebo-controlled studies, measurement of urinary ketones (1+ or greater) was higher in patients treated with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>(45%) compared to placebo (10%). No untoward clinical consequences were observed in clinical trials.</p><p>Levels of 1,25-dihydroxyvitamin D decreased in <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>treated patients relative to placebo (median percentage decrease from baseline at 2 years of 25% versus 15%, respectively) and levels of parathyroid hormone (PTH) increased in <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>treated patients relative to placebo (median percentage increase from baseline at 2 years of 29% versus 15%, respectively). Mean values for both parameters remained within normal range.</p><p>A transient increase in mean eosinophil counts was seen during the first 2 months of therapy.</p><p><u>Paediatric population </u></p><p>The safety of <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>in paediatric patients with multiple sclerosis below the age of 18 has not yet been established. In a small 24-week open-label uncontrolled study in paediatric patients with RRMS aged 13 to 17 years (120 mg twice a day for 7 days followed by 240 mg twice a day for the remainder of treatment; safety population, n=22), the safety profile appeared similar to that observed in adult patients.</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s): </strong></p><ul><li><strong>Saudi Arabia: </strong></li></ul><table border="1" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance &amp; Drug Safety Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext. 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>www.sfda.gov.sa/npc</u></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cases of overdose with <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>have been reported. The symptoms described in these cases were consistent with the known adverse reaction profile of <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>. There are no known therapeutic interventions to enhance elimination of <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>nor is there a known antidote. In the event of overdose, it is recommended that symptomatic supportive treatment be initiated as clinically indicated.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic and immunomodulating agents, ATC code: L04AX07</p><p>Mechanism of action</p><p>The mechanism by which dimethyl fumarate exerts therapeutic effects in multiple sclerosis is not fully understood. Preclinical studies indicate that dimethyl fumarate pharmacodynamic responses appear to be primarily mediated through activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway. Dimethyl fumarate has been shown to up regulate Nrf2-dependent antioxidant genes in patients (e.g. NAD(P)H dehydrogenase, quinone 1; [NQO1]).</p><p>Pharmacodynamic effects</p><p><em>Effects on the immune system </em></p><p>In preclinical and clinical studies, dimethyl fumarate demonstrated anti-inflammatory and immunomodulatory properties. Dimethyl fumarate and monomethyl fumarate, the primary metabolite of dimethyl fumarate, significantly reduced immune cell activation and subsequent release of pro-inflammatory cytokines in response to inflammatory stimuli in preclinical models. In clinical studies with psoriasis patients, dimethyl fumarate affected lymphocyte phenotypes through a down-regulation of pro-inflammatory cytokine profiles (T</p><p>H1, TH17), and biased towards anti-inflammatory production (TH2). Dimethyl fumarate demonstrated therapeutic activity in multiple models of inflammatory and neuroinflammatory injury. In Phase 3 studies in MS patients, upon treatment with <strong>DEFRA </strong><strong>&reg; </strong>mean lymphocyte counts decreased on average by approximately 30% of their baseline value over the first year with a subsequent plateau.</p><p>Clinical efficacy and safety</p><p>Two, 2-year, randomised, double-blind, placebo controlled studies [Study 1 (DEFINE) with 1234 subjects and Study 2 (CONFIRM) with 1417 subjects] of subjects with relapsing-remitting multiple sclerosis (RRMS) were performed. Subjects with progressive forms of MS were not included in these studies. Efficacy (see table below) and safety were demonstrated in subjects with Expanded Disability Status Scale (EDSS) scores ranging from 0 to 5 inclusive, who had experienced at least 1 relapse during the year prior to randomisation, or, in the 6 weeks before randomisation had a brain Magnetic Resonance Imaging (MRI) demonstrating at least one gadolinium-enhancing (Gd+) lesion. Study 2 contained a rater-blinded (i.e. study physician/ investigator assessing the response to study treatment was blinded) reference comparator of glatiramer acetate.</p><p>In Study 1, patients had the following median baseline characteristics: age 39 years, disease duration 7.0 years, EDSS score 2.0. In addition, 16% of patients had an EDSS score &gt;3.5, 28% had &ge;2 relapses in the prior year and 42% had previously received other approved MS treatments. In the MRI cohort 36% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 1.4).</p><p>In Study 2, patients had the following median baseline characteristics: age 37 years, disease duration 6.0 years, EDSS score 2.5. In addition, 17% of patients had an EDSS score &gt;3.5, 32% had &ge;2 relapses in the prior year and 30% had previously received other approved MS treatments. In the MRI cohort 45% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 2.4).</p><p>Compared to placebo, subjects treated with <strong>DEFRA </strong><strong>&reg; </strong>had a clinically meaningful and statistically significant reduction on: the primary endpoint in Study 1, proportion of subjects relapsed at 2 years; and the primary endpoint in Study 2, annualised relapse rate at 2 years.</p><p>The annualised relapse rate for glatiramer acetate and placebo was 0.286 and 0.401 respectively in Study 2, corresponding to a reduction of 29% (p=0.013), which is consistent with approved prescribing information.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>DEFINE</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>CONFIRM</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>DEFRA </strong><strong>&reg;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>DEFRA </strong><strong>&reg;</strong></p></td><td style="vertical-align:top"><p><strong>Glatiramer acetate</strong></p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>240 mg</strong></p><p>&nbsp;</p><p><strong>twice a day</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>240 mg</strong></p><p>&nbsp;</p><p><strong>twice a day</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical Endpoints</strong><strong>a</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>No. subjects</p></td><td style="vertical-align:top"><p>408</p></td><td style="vertical-align:top"><p>410</p></td><td style="vertical-align:top"><p>363</p></td><td style="vertical-align:top"><p>359</p></td><td style="vertical-align:top"><p>350</p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate</p></td><td style="vertical-align:top"><p>0.364</p></td><td style="vertical-align:top"><p>0.172***</p></td><td style="vertical-align:top"><p>0.401</p></td><td style="vertical-align:top"><p>0.224***</p></td><td style="vertical-align:top"><p>0.286*</p></td></tr><tr><td style="vertical-align:top"><p>Rate ratio</p><p>&nbsp;</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.47</p><p>&nbsp;</p><p>(0.37, 0.61)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.56</p><p>&nbsp;</p><p>(0.42, 0.74)</p></td><td style="vertical-align:top"><p>0.71</p><p>&nbsp;</p><p>(0.55, 0.93)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion relapsed</p></td><td style="vertical-align:top"><p>0.461</p></td><td style="vertical-align:top"><p>0.270***</p></td><td style="vertical-align:top"><p>0.410</p></td><td style="vertical-align:top"><p>0.291**</p></td><td style="vertical-align:top"><p>0.321**</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio</p><p>&nbsp;</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.51</p><p>&nbsp;</p><p>(0.40, 0.66)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.66</p><p>&nbsp;</p><p>(0.51, 0.86)</p></td><td style="vertical-align:top"><p>0.71</p><p>&nbsp;</p><p>(0.55, 0.92)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 12-week confirmed disability progression</p></td><td style="vertical-align:top"><p>0.271</p></td><td style="vertical-align:top"><p>0.164**</p></td><td style="vertical-align:top"><p>0.169</p></td><td style="vertical-align:top"><p>0.128#</p></td><td style="vertical-align:top"><p>0.156#</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio</p><p>&nbsp;</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.62</p><p>&nbsp;</p><p>(0.44, 0.87)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.79</p><p>&nbsp;</p><p>(0.52, 1.19)</p></td><td style="vertical-align:top"><p>0.93</p><p>&nbsp;</p><p>(0.63, 1.37)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 24 week confirmed disability progression</p></td><td style="vertical-align:top"><p>0.169</p></td><td style="vertical-align:top"><p>0.128#</p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.078#</p></td><td style="vertical-align:top"><p>0.108#</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio</p><p>&nbsp;</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.77</p><p>&nbsp;</p><p>(0.52, 1.14)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.62</p><p>&nbsp;</p><p>(0.37, 1.03)</p></td><td style="vertical-align:top"><p>0.87</p><p>&nbsp;</p><p>(0.55, 1.38)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI Endpoints</strong>b</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>No. subjects</p></td><td style="vertical-align:top"><p>165</p></td><td style="vertical-align:top"><p>152</p></td><td style="vertical-align:top"><p>144</p></td><td style="vertical-align:top"><p>147</p></td><td style="vertical-align:top"><p>161</p></td></tr><tr><td style="vertical-align:top"><p>Mean (median) number of new or newly enlarging T2 lesions over 2 years</p></td><td style="vertical-align:top"><p>16.5</p><p>&nbsp;</p><p>(7.0)</p></td><td style="vertical-align:top"><p>3.2</p><p>&nbsp;</p><p>(1.0)***</p></td><td style="vertical-align:top"><p>19.9</p><p>&nbsp;</p><p>(11.0)</p></td><td style="vertical-align:top"><p>5.7</p><p>&nbsp;</p><p>(2.0)***</p></td><td style="vertical-align:top"><p>9.6</p><p>&nbsp;</p><p>(3.0)***</p></td></tr><tr><td style="vertical-align:top"><p>Lesion mean ratio</p><p>&nbsp;</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.15</p><p>&nbsp;</p><p>(0.10, 0.23)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.29</p><p>&nbsp;</p><p>(0.21, 0.41)</p></td><td style="vertical-align:top"><p>0.46</p><p>&nbsp;</p><p>(0.33, 0.63)</p></td></tr><tr><td style="vertical-align:top"><p>Mean (median) number of Gd lesions at 2 years</p></td><td style="vertical-align:top"><p>1.8</p><p>&nbsp;</p><p>(0)</p></td><td style="vertical-align:top"><p>0.1</p><p>&nbsp;</p><p>(0)***</p></td><td style="vertical-align:top"><p>2.0</p><p>&nbsp;</p><p>(0.0)</p></td><td style="vertical-align:top"><p>0.5</p><p>&nbsp;</p><p>(0.0)***</p></td><td style="vertical-align:top"><p>0.7</p><p>&nbsp;</p><p>(0.0)**</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.10</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.26</p></td><td style="vertical-align:top"><p>0.39</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.05, 0.22)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.15, 0.46)</p></td><td style="vertical-align:top"><p>(0.24, 0.65)</p></td></tr><tr><td style="vertical-align:top"><p>Mean (median) number of new T1 hypointense lesions over 2 years</p></td><td style="vertical-align:top"><p>5.7</p><p>&nbsp;</p><p>(2.0)</p></td><td style="vertical-align:top"><p>2.0</p><p>&nbsp;</p><p>(1.0)***</p></td><td style="vertical-align:top"><p>8.1</p><p>&nbsp;</p><p>(4.0)</p></td><td style="vertical-align:top"><p>3.8</p><p>&nbsp;</p><p>(1.0)***</p></td><td style="vertical-align:top"><p>4.5</p><p>&nbsp;</p><p>(2.0)**</p></td></tr><tr><td style="vertical-align:top"><p>Lesion mean ratio</p><p>&nbsp;</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.28</p><p>&nbsp;</p><p>(0.20, 0.39)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.43</p><p>&nbsp;</p><p>(0.30, 0.61)</p></td><td style="vertical-align:top"><p>0.59</p><p>&nbsp;</p><p>(0.42, 0.82)</p></td></tr></tbody></table><p><sup>a</sup>All analyses of clinical endpoints were intent-to-treat; <sup>b</sup>MRI analysis used MRI cohort</p><p>*P-value &lt; 0.05; **P-value &lt; 0.01; ***P-value &lt; 0.0001; #not statistically significant</p><p>Efficacy in patients with high disease activity:</p><p>Consistent treatment effect on relapses in a subgroup of patients with high disease activity was observed, whilst the effect on time to 3-month sustained disability progression was not clearly established. Due to the design of the studies, high disease activity was defined as follows:</p><p>- Patients with 2 or more relapses in one year, and with one or more Gd-enhancing lesions on brain MRI (n=42 in DEFINE; n=51 in CONFIRM) or,</p><p>- Patients who have failed to respond to a full and adequate course (at least one year of treatment) of beta-interferon, having had at least 1 relapse in the previous year while on therapy, and at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gd-enhancing lesion, or patients having an unchanged or increased relapse rate in the prior year as compared to the previous 2 years (n=177 in DEFINE; n=141 in CONFIRM).</p><p>Paediatric population</p><p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong>was evaluated in a prospective open-label, uncontrolled study in 22 paediatric patients with RRMS aged 13 to 17 years (4 patients aged &le;14 years). Subjects received <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>120 mg twice a day for 7 days followed by 240 mg twice a day for 24 weeks. The median number of new or newly enlarging T2 hyperintense lesions changed from 2 in the 8 week pre-treatment evaluation period to 0 in the final 8 weeks of the treatment period (median change -2, n=16). These data should be considered cautiously regarding limitations of the study design (no control arm, pre- versus post-dose comparison) (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Orally administered dimethyl fumarate undergoes rapid presystemic hydrolysis by esterases and is converted to its primary metabolite, monomethyl fumarate, which is also active. Dimethyl fumarate is not quantifiable in plasma following oral administration of <strong>DEFRA </strong><strong><sup>&reg;</sup></strong>. Therefore, all pharmacokinetic analyses related to dimethyl fumarate were performed with plasma monomethyl fumarate concentrations. Pharmacokinetic data were obtained in subjects with multiple sclerosis and healthy volunteers.</p><p>Absorption</p><p>The T<sub>max </sub>of monomethyl fumarate is 2 to 2.5 hours. As <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>gastro-resistant hard capsules contain microtablets, which are protected by an enteric coating, absorption does not commence until they leave the stomach (generally less than 1 hour). Following 240 mg twice a day administered with food, the median peak (C<sub>max</sub>) was 1.72 mg/l and overall area under the curve (AUC) exposure was 8.02 h.mg/l in subjects with multiple sclerosis. Overall, C<sub>max </sub>and AUC increased approximately dose- proportionally in the dose range studied (120 mg to 360 mg). In subjects with multiple sclerosis, two 240 mg doses were administered 4 hours apart as part of a three times a day dosing regimen. This resulted in a minimal accumulation of exposure yielding an increase in the median Cmax of 12% compared to the twice daily dosing (1.72 mg/l for twice daily compared to 1.93 mg/l for three times daily) with no safety implications.</p><p>Food does not have a clinically significant effect on exposure of dimethyl fumarate. However, <strong>DEFRA </strong><strong><sup>&reg; </sup></strong>should be taken with food due to improved tolerability with respect to flushing or gastrointestinal adverse events (see section 4.2).</p><p>Distribution</p><p>The apparent volume of distribution following oral administration of 240 mg dimethyl fumarate varies between 60 L and 90 L. Human plasma protein binding of monomethyl fumarate generally ranges between 27% and 40%.</p><p>Biotransformation</p><p>In humans, dimethyl fumarate is extensively metabolised with less than 0.1% of the dose excreted as unchanged dimethyl fumarate in urine. It is initially metabolised by esterases, which are ubiquitous in the gastrointestinal tract, blood and tissues, before it reaches the systemic circulation. Further metabolism occurs through the tricarboxylic acid cycle, with no involvement of the cytochrome P450 (CYP) system. A single 240 mg <sup>14</sup>C-dimethyl fumarate dose study identified glucose as the predominant metabolite in human plasma. Other circulating metabolites included fumaric acid, citric acid and monomethyl fumarate. The downstream metabolism of fumaric acid occurs through the tricarboxylic acid cycle, with exhalation of CO<sub>2 </sub>serving as a primary route of elimination.</p><p>Elimination</p><p>Exhalation of CO<sub>2 </sub>is the primary route of dimethyl fumarate elimination accounting for 60% of the dose. Renal and faecal elimination are secondary routes of elimination, accounting for 15.5% and 0.9% of the dose respectively.</p><p>The terminal half-life of monomethyl fumarate is short (approximately 1 hour) and no circulating monomethyl fumarate is present at 24 hours in the majority of individuals. Accumulation of parent drug or monomethyl fumarate does not occur with multiple doses of dimethyl fumarate at the therapeutic regimen.</p><p>Linearity</p><p>Dimethyl fumarate exposure increases in an approximately dose proportional manner with single and multiple doses in the 120 mg to 360 mg dose range studied.</p><p>Pharmacokinetics in special patient groups</p><p>Based on the results of Analysis of Variance (ANOVA), body weight is the main covariate of exposure (by C<sub>max </sub>and AUC) in RRMS subjects, but did not affect safety and efficacy measures evaluated in the clinical studies.</p><p>Gender and age did not have a clinically significant impact on the pharmacokinetics of dimethyl fumarate. The pharmacokinetics in patients aged 65 and over has not been studied.</p><p><em>Paediatric population </em></p><p>The pharmacokinetic profile of 240 mg dimethyl fumarate twice a day was evaluated in a small, open-label, uncontrolled study in patients with RRMS aged 13 to 17 years (n=21). The pharmacokinetics of <strong>DEFRA <sup>&reg; </sup></strong>in these adolescent patients was consistent with that previously observed in adult patients (C<sub>max</sub>: 2.00&plusmn;1.29 mg/l; AUC<sub>0-12hr</sub>: 3.62&plusmn;1.16 h.mg/l, which corresponds to an overall daily AUC of 7.24 h.mg/l).</p><p><em>Renal impairment </em></p><p>Since the renal pathway is a secondary route of elimination for dimethyl fumarate accounting for less than 16% of the dose administered, evaluation of pharmacokinetics in individuals with renal impairment was not conducted.</p><p><em>Hepatic impairment </em></p><p>As dimethyl fumarate and monomethyl fumarate are metabolised by esterases, without the involvement of the CYP450 system, evaluation of phamacokinetics in individuals with hepatic impairment was not conducted.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions described in the Toxicology and Reproduction toxicity sections below were not observed in clinical studies, but were seen in animals at exposure levels similar to clinical exposure levels.</p><p>Mutagenesis</p><p>Dimethyl fumarate and mono-methylfumarate were negative in a battery of <em>in vitro </em>assays (Ames, chromosomal aberration in mammalian cells). Dimethyl fumarate was negative in the <em>in vivo </em>micronucleus assay in the rat.</p><p>Carcinogenesis</p><p>Carcinogenicity studies of dimethyl fumarate were conducted for up to 2 years in mice and rats. Dimethyl fumarate was administered orally at doses of 25, 75, 200 and 400 mg/kg/day in mice, and at doses of 25, 50, 100, and 150 mg/kg/day in rats. In mice, the incidence of renal tubular carcinoma was increased at 75 mg/kg/day, at equivalent exposure (AUC) to the recommended human dose. In rats, the incidence of renal tubular carcinoma was increased at 100 mg/kg/day, approximately 2 times higher exposure than the recommended human dose. The relevance of these findings to human risk is unknown.</p><p>The incidence of squamous cell papilloma and carcinoma in the nonglandular stomach (forestomach) was increased at equivalent exposure to the recommended human dose in mice and below exposure to the recommended human dose in rats (based on AUC). The forestomach in rodents does not have a human counterpart.</p><p>Toxicology</p><p>Nonclinical studies in rodent, rabbits, and monkeys were conducted with a dimethyl fumarate suspension (dimethyl fumarate in 0.8% hydroxypropyl methylcellulose) administered by oral gavage. The chronic dog study was conducted with oral administration of the dimethyl fumarate capsule.</p><p>Kidney changes were observed after repeated oral administration of dimethyl fumarate in mice, rats, dogs, and monkeys. Renal tubule epithelial regeneration, suggestive of injury, was observed in all species. Renal tubular hyperplasia was observed in rats with life time dosing (2-year study). In dogs that received daily oral doses of dimethyl fumarate for 11 months, the margin calculated for cortical atrophy was observed at 3 times the recommended dose based on AUC. In monkeys that received daily oral doses of dimethyl fumarate for 12 months, single cell necrosis was observed at 2 times the recommended dose based on AUC. Interstitial fibrosis and cortical atrophy were observed at 6 times the recommended dose based on AUC. The relevance of these findings to humans is not known.</p><p>In the testes, degeneration of the seminiferous epithelium was seen in rats and dogs. The findings were observed at approximately the recommended dose in rats and 3 times the recommended dose in dogs (AUC basis). The relevance of these findings to humans is not known.</p><p>Findings in the forestomach of mice and rats consisted of squamous epithelial hyperplasia and hyperkeratosis; inflammation; and squamous cell papilloma and carcinoma in studies of 3 months or longer in duration. The forestomach of mice and rats does not have a human counterpart.</p><p>Reproduction toxicity</p><p>Oral administration of dimethyl fumarate to male rats at 75, 250, and 375 mg/kg/day prior to and during mating had no effects on male fertility up to the highest dose tested (at least 2 times the recommended dose on an AUC basis). Oral administration of dimethyl fumarate to female rats at 25, 100, and 250 mg/kg/day prior to and during mating, and continuing to Day 7 of gestation, induced reduction in the number of estrous stages per 14 days and increased the number of animals with prolonged diestrus at the highest dose tested (11 times the recommended dose on an AUC basis). However, these changes did not affect fertility or the number of viable fetuses produced.</p><p>Dimethyl fumarate has been shown to cross the placental membrane into fetal blood in rats and rabbits, with ratios of fetal to maternal plasma concentrations of 0.48 to 0.64 and 0.1 respectively. No malformations were observed at any dose of dimethyl fumarate in rats or rabbits. Administration of dimethyl fumarate at oral doses of 25, 100, and 250 mg/kg/day to pregnant rats during the period of organogenesis resulted in maternal adverse effects at 4 times the recommended dose on an AUC basis, and low fetal weight and delayed ossification (metatarsals and hindlimb phalanges) at 11 times the recommended dose on an AUC basis. The lower fetal weight and delayed ossification were considered secondary to maternal toxicity (reduced body weight and food consumption).</p><p>Oral administration of dimethyl fumarate at 25, 75, and 150 mg/kg/day to pregnant rabbits during organogenesis had no effect on embryo-fetal development and resulted in reduced maternal body weight at 7 times the recommended dose and increased abortion at 16 times the recommended dose, on an AUC basis.</p><p>Oral administration of dimethyl fumarate at 25, 100, and 250 mg/kg/day to rats during pregnancy and lactation resulted in lower body weights in the F1 offspring, and delays in sexual maturation in F1 males at 11 times the recommended dose on an AUC basis. There were no effects on fertility in the F1 offspring. The lower offspring body weight was considered secondary to maternal toxicity</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>1. Microcrystalline Cellulose (Avicel PH 112)</p></td></tr><tr><td style="vertical-align:top"><p>2. Croscarmellose Sodium (Ac Di Sol SD-711)</p></td></tr><tr><td style="vertical-align:top"><p>3. Colloidal Silicon Dioxide (Aerosil 200)</p></td></tr><tr><td style="vertical-align:top"><p>4. Magnesium Stearate (Tablube)</p></td></tr><tr><td style="vertical-align:top"><p>5. Talc</p></td></tr><tr><td style="vertical-align:top"><p>6. Isopropyl Alcohol</p></td></tr><tr><td style="vertical-align:top"><p>7. Methacrylic Acid Ethyl Acrylate Copolymer Methacrylic Acid Ethyl Acrylate Copolymer Type A Eudragit L 100 55</p></td></tr><tr><td style="vertical-align:top"><p>8. Triethyl Citrate</p></td></tr><tr><td style="vertical-align:top"><p>9. Talc (Enteric coate )</p><p>10. Triethyl citrate (Enteric coat )</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:664px"><tbody><tr><td style="vertical-align:top"><p>11. Methacrylic Acid Ethyl Acrylate Copolymer Dispersion Methacrylic Acid Copolymer Dispersion Eudragit L 30 D 55(enteric coat )</p></td></tr><tr><td style="vertical-align:top">&nbsp;12. Purified Water</td></tr></tbody></table></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30<sup>o</sup>C in a dry place. Protect from light.</p><p>Keep out of reach of children.</p><p>As with all medicines, keep this product out of the reach of children.</p><p>Do not keep outdated medicine or medicine no longer needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong><strong>120mg delayed release capsules: </strong>25 micron Aluminium foil / 6-8 gsm HSL,/ Clear PVC/PE/PVdC film 250/25/90 gsm</p><p><strong>DEFRA </strong><strong><sup>&reg; </sup></strong><strong>240mg delayed release capsules: </strong>25 micron Aluminium foil / 6-8 gsm HSL,/ Clear PVC/PE/PVdC film 250/25/90 gsm</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>No special requirements.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
c. Marketing authorization holder: 
MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia. 
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Oct-19
SPC-048-00

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>